Source:http://linkedlifedata.com/resource/pubmed/id/18382216
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-4-2
|
| pubmed:abstractText |
The promise of pharmacogenomics is that it will one day result in targeted heart failure therapy that maximizes individual benefit and diminishes risk. Recent reports from the Beta Blocker Evaluation Survival and African American Heart Failure clinical trials provide a roadmap of how this promise may soon be realized. This review will discuss recent investigations of pharmacogenomics in heart failure, and the challenge of converting genomic heterogeneity into a usable clinical tool.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0268-4705
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
261-8
|
| pubmed:meshHeading |
pubmed-meshheading:18382216-African Americans,
pubmed-meshheading:18382216-European Continental Ancestry Group,
pubmed-meshheading:18382216-Genetic Heterogeneity,
pubmed-meshheading:18382216-Genotype,
pubmed-meshheading:18382216-Heart Failure,
pubmed-meshheading:18382216-Humans,
pubmed-meshheading:18382216-Pharmacogenetics,
pubmed-meshheading:18382216-Polymorphism, Genetic,
pubmed-meshheading:18382216-Randomized Controlled Trials as Topic
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Emerging role of pharmacogenomics in heart failure.
|
| pubmed:affiliation |
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA. mcnamaradm@upmc.edu
|
| pubmed:publicationType |
Journal Article,
Review
|